Pioneering the future of CAR-T therapy through revolutionary AI-driven CRS management solutions
At Nanotrol™ Therapeutics, we are revolutionizing cancer treatment by solving one of the most critical challenges in CAR-T cell therapy: Cytokine Release Syndrome (CRS). Our breakthrough AI-driven platform combines enhanced nanoformulated therapeutics with real-time biomarker optimization to dramatically improve patient outcomes.
We believe that every cancer patient deserves access to the life-saving potential of CAR-T therapy without the fear of severe complications. Through our innovative technology, we're making CAR-T therapy safer, more effective, and accessible to patients worldwide.
Our vision extends beyond just treating CRS – we're building the foundation for next-generation precision medicine that adapts in real-time to each patient's unique biology, setting new standards for therapeutic optimization and patient care.
World-class expertise in biotechnology, AI, and pharmaceutical development
Key milestones in our journey to revolutionize CRS management
Nanotrol™ Therapeutics founded by Dr. Izhar Hasan MD PhD.
Completed initial AI algorithm development and Nanotrol™ formulation optimization. Filed first provisional patents for core technology platform.
IV nanomanufacturing, Oral micronized Salsalate PK study completed/IND submission.
IV nanomanufacturing, Oral micronized Salsalate PK study completed/IND submission.
dissolution study performed.
Predictive model/Nanotrol for CRS management